Skip to main content
SpringerLink
Log in

Multicenter Trials

  • Chapter
  • First Online:
Fundamentals of Clinical Trials

Abstract

A multicenter trial is a collaborative effort that involves more than one independent center in the tasks of enrolling and following study participants. Early contributions to the design of these trials were made by Hill [1], and a general discussion of methods was provided by Greenberg [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fleiss JL. Multicentre clinical trials: Bradford Hill’s contributions and some subsequent developments. Stat Med 1982;1:353–359.

    Article  Google Scholar 

  2. Greenberg BG. Conduct of cooperative field and clinical trials. Am Stat 1959;13:13–28.

    Google Scholar 

  3. Klimt CR. Principles of multi-center clinical studies. In Boissel JP, Klimt CR. Multi-center Controlled Trials. Principles and Problems. 1979; INSERM, Paris.

    Google Scholar 

  4. Levin WC, Fink DJ, Porter S, et al. Cooperative clinical investigation: a modality of medical science. JAMA 1974;227:1295–1296.

    Article  Google Scholar 

  5. Coronary Drug Project Research Group. PL Canner (ed.). The Coronary Drug Project: methods and lessons of a multicenter clinical trial. Control Clin Trials 1983;4:273–541.

    Google Scholar 

  6. Meinert CL. Clinical Trials. Design, Conduct and Analysis. New York: Oxford University Press, 1986.

    Google Scholar 

  7. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661–669.

    Article  Google Scholar 

  8. Croke G. Recruitment for the National Cooperative Gallstone Study. Clin Pharmacol Ther 1979;25:691–694.

    Google Scholar 

  9. Shea S, Bigger JT, Campion J, et al. Enrollment in clinical trials: institutional factors affecting enrollment in the Cardiac Arrhythmia Suppression Trial (CAST). Control Clin Trials 1992;13:466–486.

    Article  Google Scholar 

  10. Fisher MR, Roecker EB, DeMets DL. The role of an independent statistical analysis center in the industry-modified National Institutes of Health model. Drug Inf J 2001;35:115–129.

    Google Scholar 

  11. Byington RP, for the Beta-Blocker Heart Attack Trial Research Group. Beta-Blocker Heart Attack Trial: design, methods, and baseline results. Control Clin Trials 1984;5:382–437.

    Google Scholar 

  12. Meinert CL. Organization of multicenter clinical trials. Control Clin Trials 1981;1:305–312.

    Article  Google Scholar 

  13. Lachin JM, Marks JW, Schoenfield LJ, et al. Design and methodological considerations in the National Cooperative Gallstone Study: a multicenter clinical trial. Control Clin Trials 1981;2:177–229.

    Article  Google Scholar 

  14. Carbone PP. Organization of clinical oncology in the U.S.A.: role of cancer centers, cooperative groups and community hospitals. Eur J Cancer Clin Oncol 1985;21:119–154.

    Article  Google Scholar 

  15. Carbone PP, Tormey DC. Organizing multicenter trials: lessons from the cooperative oncology groups. Prev Med 1991;20:162–169.

    Article  Google Scholar 

  16. Friedman L, DeMets D. The data monitoring committee: how it operates and why. IRB 1981;3:6–8.

    Article  Google Scholar 

  17. Fleming TR, DeMets DL. Monitoring of clinical trials: issues and recommendations. Control Clin Trials 1993;14:183–197.

    Article  Google Scholar 

  18. Angell M, Kassirer JP. Setting the research straight in the breast-cancer trials. N Engl J Med 1994;330:1448–1450.

    Article  Google Scholar 

  19. Cohen J. Clinical trial monitoring: hit or miss? Science 1994;264:1534–1537.

    Article  Google Scholar 

  20. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984;3:409–422.

    Article  Google Scholar 

  21. Eisenstein EL, Lemons PW 2nd, Tardiff BE, et al. Reducing the costs of phase III cardiovascular clinical trials. Am Heart J 2005;149:482–488.

    Article  Google Scholar 

  22. Kassirer JP, Angell M. On authorship and acknowledgments. N Engl J Med 1991;325:1510–1512.

    Article  Google Scholar 

  23. Goldberg MF. Changes in the archives. Arch Ophthalmol 1993;111:39–40.

    Article  Google Scholar 

  24. Meinert CL. In defense of the corporate author for multicenter trials. Control Clin Trials 1993;14:255–260.

    Article  Google Scholar 

  25. Winston DJ, Ho WG, Gale RP. Prophylactic granulocyte transfusions during chemotherapy of acute nonlymphocytic leukemia. Ann Intern Med 1981;94:616–622.

    Article  Google Scholar 

  26. Strauss RG, Connett JE, Gale RP, et al. A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia. N Engl J Med 1981;305:597–603.

    Article  Google Scholar 

  27. Remington RD. Problems of university-based scientists associated with clinical trials. Clin Pharmacol Ther 1979;25:662–665.

    Google Scholar 

  28. Sackett DL, Naylor CD. Should there be early publication of ancillary studies prior to the first primary report of an unblinded randomized clinical trial? J Clin Epidemiol 1993;46:395–402.

    Article  Google Scholar 

  29. Akkerhuis KM, Deckers JW, Boersma E, et al, for the PURSUIT Investigators. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes: results from PURSUIT. Eur Heart J 2000;21:371–381.

    Google Scholar 

  30. Wedel H, DeMets D, Deedwania P, et al, on behalf of the MERIT-HF Study Group. Challenges of subgroup analyses in multinational clinical trials. Experiences from the MERIT-HF trial. Am Heart J 2001;143:502–511.

    Google Scholar 

  31. O’Shea JC, Califf RM. International differences in treatment effects in cardiovascular clinical trials. Am Heart J 2001;141:875–889.

    Article  Google Scholar 

  32. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials 1998;19:159–166.

    Article  Google Scholar 

  33. Tognoni G, Alli C, Avanzini F, et al. Randomised clinical trials in general practice: lessons from a failure. Br Med J 1991;303:969–971.

    Article  Google Scholar 

  34. Eisenstein EL, Collins R, Cracknell BS, et al. Sensible approaches for reducing clinical trial costs. Clin Trials 2008;5:75–84.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bethesda, MD, USA

    Lawrence M. Friedman

  2. School of Medicine, Wake Forest University, Winston-Salem, NC, USA

    Curt D. Furberg

  3. Department of Biostatistics & Medical Informatics, University of Wisconsin, Madison, WI, USA

    David L. DeMets

Authors
  1. Lawrence M. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Curt D. Furberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David L. DeMets
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lawrence M. Friedman .

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer New York

About this chapter

Cite this chapter

Friedman, L.M., Furberg, C.D., DeMets, D.L. (2010). Multicenter Trials. In: Fundamentals of Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1586-3_20

Download citation

Publish with us

Policies and ethics

Search

Navigation